© 2005 Oxford University Press
ARTICLE |
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non–Small-Cell Lung Cancer
for the French Thoracic Oncology Collaborative Group (GCOT)
Affiliations of authors: Chest Disease Department, Jean Minjoz University Hospital, Besançon, France (VW, AD); Chest Disease Department, University Hospital, Strasbourg, France (EQ); Chest Disease Department, University Hospital, Grenoble, France (DM-S); Biostatistics, University Hospital, Besançon, France (MM, MP); Chest Disease Department, General Hospital, Belfort, France (J-LB); Chest Disease Department, General Hospital, Vesoul, France (DD); Chest Disease Department, General Hospital, Saint Omer, France (PR); Chest Disease Department, University Hospital, Nancy, France (M-AH); Chest Disease Department, Tenon University Hospital, Paris, France (BM); Chest Disease Department, General Hospital, Nevers, France (DH); Chest Disease Department, General Hospital, Verdun, France (M-CL); Chest Disease Department, General Hospital, Le Mans, France (F-XL)
Correspondence to: Alain Depierre, MD, Service de pneumologie, Centre Hospitalier Universitaire Jean Minjoz, Boulevard Fleming, 25030 Besançon cedex, France ( e-mail: pneumo-depierre{at}ufc-chu.univ-fcomte.fr).
Background: Prolongation of chemotherapy duration, usually referred to as maintenance chemotherapy, has been considered as an approach to improve survival of patients with advanced non–small-cell lung cancer (NSCLC). If the maintenance regimen differs from the induction regimen, patients will receive not only higher total doses of chemotherapy but also earlier delivery of non–cross-resistant agents. We conducted a randomized trial to compare maintenance vinorelbine therapy with observation in previously untreated patients who responded to induction treatment with mitomycin–ifosfamide–cisplatin (MIC). Methods: Patients with stage IIIB NSCLC were treated with two monthly MIC cycles followed by radiotherapy; those with "wet" stage IIIB (pleural or pericardial involvement), with stage IIIB with supraclavicular node involvement, or stage IV (i.e., metastatic) NSCLC were treated with four monthly MIC cycles. Patients who responded to induction treatment were randomly assigned to receive intravenous vinorelbine at a dose of 25 mg·m–2·wk–1 for 6 months or no further treatment. Survival comparisons used the log-rank test and the Cox regression adjusted for stage. All statistical tests were two-sided. Results: A total of 573 patients were registered, of whom 227 responded to induction treatment and 181 were randomly assigned (91 to maintenance vinorelbine and 90 to observation) between January 1994 and March 2000. One- and 2-year survival rates were 42.2% and 20.1% in the vinorelbine arm and 50.6% and 20.2% in the observation arm, respectively (log-rank P = .48). The hazard ratio of survival after adjustment on stage, in the vinorelbine arm relative to the observation arm, was 1.08 (95% confidence interval = 0.79 to 1.47; P = .65). There was also no difference between arms in progression-free survival (log-rank P = .32). Conclusion: Maintenance vinorelbine did not improve survival of patients with advanced NSCLC who responded to induction MIC treatment. Nevertheless, other agents, including docetaxel and targeted agents, should be evaluated as maintenance agents before the concept is abandoned.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Ramalingam and C. Belani Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Oncologist, January 1, 2008; 13(suppl_1): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski and T. E. Stinchcombe Duration of First-Line Chemotherapy in Advanced Non Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent Therapies J. Clin. Oncol., November 20, 2007; 25(33): 5155 - 5157. [Full Text] [PDF]
|
|
|
|
|
|
J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions J. Clin. Oncol., September 10, 2007; 25(26): 4127 - 4136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature Oncologist, April 1, 2007; 12(4): 451 - 464. [Abstract] [Full Text] [PDF]
|
|